Search

Your search keyword '"Kaempf, Andy"' showing total 264 results
Start Over Author "Kaempf, Andy"
264 results on '"Kaempf, Andy"'

2. The Chronic Lymphocytic Leukemia Comorbidity Index (CLL-CI): A Three-Factor Comorbidity Model.

Author

Gordon, Max, Kaempf, Andy, Sitlinger, Andrea, Shouse, Geoffrey, Mei, Matthew, Brander, Danielle, Salous, Tareq, Hill, Brian, Alqahtani, Hamood, Choi, Michael, Churnetski, Michael, Cohen, Jonathon, Stephens, Deborah, Siddiqi, Tanya, Rivera, Xavier, Persky, Daniel, Wisniewski, Paul, Patel, Krish, Shadman, Mazyar, Park, Byung, and Danilov, Alexey

Subjects
Adult, Aged, Aged, 80 and over, Humans, Leukemia, Lymphocytic, Chronic, B-Cell, Middle Aged, Progression-Free Survival, Proportional Hazards Models, Retrospective Studies
Abstract

PURPOSE: Comorbid medical conditions define a subset of patients with chronic lymphocytic leukemia (CLL) with poor outcomes. However, which comorbidities are most predictive remains understudied. EXPERIMENTAL DESIGN: We conducted a retrospective analysis from 10 academic centers to ascertain the relative importance of comorbidities assessed by the cumulative illness rating scale (CIRS). The influence of specific comorbidities on event-free survival (EFS) was assessed in this derivation dataset using random survival forests to construct a CLL-specific comorbidity index (CLL-CI). Cox models were then fit to this dataset and to a single-center, independent validation dataset. RESULTS: The derivation and validation sets comprised 570 patients (59% receiving Bruton tyrosine kinase inhibitor, BTKi) and 167 patients (50% receiving BTKi), respectively. Of the 14 CIRS organ systems, three had a strong and stable influence on EFS: any vascular, moderate/severe endocrine, moderate/severe upper gastrointestinal comorbidity. These were combined to create the CLL-CI score, which was categorized into 3 risk groups. In the derivation dataset, the median EFS values were 58, 33, and 20 months in the low, intermediate, and high-risk groups, correspondingly. Two-year overall survival (OS) rates were 96%, 91%, and 82%. In the validation dataset, median EFS values were 81, 40, and 23 months (two-year OS rates 97%/92%/88%), correspondingly. Adjusting for prognostic factors, CLL-CI was significantly associated with EFS in patients treated with either chemo-immunotherapy or with BTKi in each of our 2 datasets. CONCLUSIONS: The CLL-CI is a simplified, CLL-specific comorbidity index that can be easily applied in clinical practice and correlates with survival in CLL.

Published
2021

3. An expanded universe of cancer targets

Author

Hahn, William C, Bader, Joel S, Braun, Theodore P, Califano, Andrea, Clemons, Paul A, Druker, Brian J, Ewald, Andrew J, Fu, Haian, Jagu, Subhashini, Kemp, Christopher J, Kim, William, Kuo, Calvin J, McManus, Michael T, B. Mills, Gordon, Mo, Xiulei, Sahni, Nidhi, Schreiber, Stuart L, Talamas, Jessica A, Tamayo, Pablo, Tyner, Jeffrey W, Wagner, Bridget K, Weiss, William A, Gerhard, Daniela S, Dancik, Vlado, Gill, Shubhroz, Hua, Bruce, Sharifnia, Tanaz, Viswanathan, Vasanthi, Zou, Yilong, Dela Cruz, Filemon, Kung, Andrew, Stockwell, Brent, Boehm, Jesse, Dempster, Josh, Manguso, Robert, Vazquez, Francisca, Cooper, Lee AD, Du, Yuhong, Ivanov, Andrey, Lonial, Sagar, Moreno, Carlos S, Niu, Qiankun, Owonikoko, Taofeek, Ramalingam, Suresh, Reyna, Matthew, Zhou, Wei, Grandori, Carla, Shmulevich, Ilya, Swisher, Elizabeth, Cai, Jitong, Chan, Issac S, Dunworth, Matthew, Ge, Yuchen, Georgess, Dan, Grasset, Eloïse M, Henriet, Elodie, Knútsdóttir, Hildur, Lerner, Michael G, Padmanaban, Veena, Perrone, Matthew C, Suhail, Yasir, Tsehay, Yohannes, Warrier, Manisha, Morrow, Quin, Nechiporuk, Tamilla, Long, Nicola, Saultz, Jennifer, Kaempf, Andy, Minnier, Jessica, Tognon, Cristina E, Kurtz, Stephen E, Agarwal, Anupriya, Brown, Jordana, Watanabe-Smith, Kevin, Vu, Tania Q, Jacob, Thomas, Yan, Yunqi, Robinson, Bridget, Lind, Evan F, Kosaka, Yoko, Demir, Emek, Estabrook, Joseph, Grzadkowski, Michael, Nikolova, Olga, Chen, Ken, Deneen, Ben, Liang, Han, Bassik, Michael C, Bhattacharya, Asmita, Brennan, Kevin, Curtis, Christina, Gevaert, Olivier, Ji, Hanlee P, Karlsson, Kasper AJ, Karagyozova, Kremena, Lo, Yuan-Hung, Liu, Katherine, Nakano, Michitaka, Sathe, Anuja, and Smith, Amber R

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Cancer, Biotechnology, Genetics, Orphan Drug, Rare Diseases, 2.1 Biological and endogenous factors, Aetiology, Animals, Clinical Trials as Topic, Disease Models, Animal, Drug Delivery Systems, Genomics, Humans, Neoplasms, Tumor Escape, Tumor Microenvironment, Cancer Target Discovery and Development Network, Biological Sciences, Medical and Health Sciences, Developmental Biology, Biological sciences, Biomedical and clinical sciences
Abstract

The characterization of cancer genomes has provided insight into somatically altered genes across tumors, transformed our understanding of cancer biology, and enabled tailoring of therapeutic strategies. However, the function of most cancer alleles remains mysterious, and many cancer features transcend their genomes. Consequently, tumor genomic characterization does not influence therapy for most patients. Approaches to understand the function and circuitry of cancer genes provide complementary approaches to elucidate both oncogene and non-oncogene dependencies. Emerging work indicates that the diversity of therapeutic targets engendered by non-oncogene dependencies is much larger than the list of recurrently mutated genes. Here we describe a framework for this expanded list of cancer targets, providing novel opportunities for clinical translation.

Published
2021

4. A validated composite comorbidity index predicts outcomes of CAR T-cell therapy in patients with diffuse large B-cell lymphoma

Author

Shouse, Geoffrey, Kaempf, Andy, Gordon, Max J., Artz, Andy, Yashar, David, Sigmund, Audrey M., Smilnak, Gordon, Bair, Steven M., Mian, Agrima, Fitzgerald, Lindsey A., Bajwa, Amneet, Jaglowski, Samantha, Bailey, Neil, Shadman, Mazyar, Patel, Krish, Stephens, Deborah M., Kamdar, Manali, Hill, Brian T., Gauthier, Jordan, Karmali, Reem, Nastoupil, Loretta J., Kittai, Adam S., and Danilov, Alexey V.

Published
2023
Full Text
View/download PDF

11. Comparison of bleeding and thrombotic outcomes in veno‐venous extracorporeal membrane oxygenation: Heparin versus bivalirudin

Author

Kartika, Thomas, primary, Mathews, Rick, additional, Migneco, Gina, additional, Bundy, Taylor, additional, Kaempf, Andy J., additional, Pfeffer, Michael, additional, DeLoughery, Thomas G., additional, Moore, Kerry, additional, Beardshear, Rachel, additional, Oetken, Heath J., additional, Case, Jonathan, additional, Hinds, Monica T., additional, McCarty, Owen J. T., additional, Shatzel, Joseph J., additional, Zonies, David, additional, and Zakhary, Bishoy L., additional

Published
2023
Full Text
View/download PDF

13. Table S4 from Clinical Correlates of Venetoclax-Based Combination Sensitivities to Augment Acute Myeloid Leukemia Therapy

Author

Eide, Christopher A., primary, Kurtz, Stephen E., primary, Kaempf, Andy, primary, Long, Nicola, primary, Joshi, Sunil Kumar, primary, Nechiporuk, Tamilla, primary, Huang, Ariane, primary, Dibb, Charles A., primary, Taylor, Akosha, primary, Bottomly, Daniel, primary, McWeeney, Shannon K., primary, Minnier, Jessica, primary, Lachowiez, Curtis A., primary, Saultz, Jennifer N., primary, Swords, Ronan T., primary, Agarwal, Anupriya, primary, Chang, Bill H., primary, Druker, Brian J., primary, and Tyner, Jeffrey W., primary

Published
2023
Full Text
View/download PDF

14. Supplementary Figure S2 from Clinical Correlates of Venetoclax-Based Combination Sensitivities to Augment Acute Myeloid Leukemia Therapy

Author

Eide, Christopher A., primary, Kurtz, Stephen E., primary, Kaempf, Andy, primary, Long, Nicola, primary, Joshi, Sunil Kumar, primary, Nechiporuk, Tamilla, primary, Huang, Ariane, primary, Dibb, Charles A., primary, Taylor, Akosha, primary, Bottomly, Daniel, primary, McWeeney, Shannon K., primary, Minnier, Jessica, primary, Lachowiez, Curtis A., primary, Saultz, Jennifer N., primary, Swords, Ronan T., primary, Agarwal, Anupriya, primary, Chang, Bill H., primary, Druker, Brian J., primary, and Tyner, Jeffrey W., primary

Published
2023
Full Text
View/download PDF

15. Data from Clinical Correlates of Venetoclax-Based Combination Sensitivities to Augment Acute Myeloid Leukemia Therapy

Author

Eide, Christopher A., primary, Kurtz, Stephen E., primary, Kaempf, Andy, primary, Long, Nicola, primary, Joshi, Sunil Kumar, primary, Nechiporuk, Tamilla, primary, Huang, Ariane, primary, Dibb, Charles A., primary, Taylor, Akosha, primary, Bottomly, Daniel, primary, McWeeney, Shannon K., primary, Minnier, Jessica, primary, Lachowiez, Curtis A., primary, Saultz, Jennifer N., primary, Swords, Ronan T., primary, Agarwal, Anupriya, primary, Chang, Bill H., primary, Druker, Brian J., primary, and Tyner, Jeffrey W., primary

Published
2023
Full Text
View/download PDF

19. Comparison of bleeding and thrombotic outcomes in veno‐venous extracorporeal membrane oxygenation: Heparin versus bivalirudin.

Author

Kartika, Thomas, Mathews, Rick, Migneco, Gina, Bundy, Taylor, Kaempf, Andy J., Pfeffer, Michael, DeLoughery, Thomas G., Moore, Kerry, Beardshear, Rachel, Oetken, Heath J., Case, Jonathan, Hinds, Monica T., McCarty, Owen J. T., Shatzel, Joseph J., Zonies, David, and Zakhary, Bishoy

Subjects
EXTRACORPOREAL membrane oxygenation, BIVALIRUDIN, HEPARIN, RED blood cell transfusion, BLOOD platelets
Abstract

Objectives: We aimed to evaluate thrombotic and hemorrhagic complications with heparin versus bivalirudin use in veno‐venous extracorporeal membrane oxygenation (V‐V ECMO). Methods: We performed a retrospective cohort study of adult patients placed on V‐V ECMO with intravenous anticoagulation with either heparin or bivalirudin. Time to thrombotic event and major bleed were analyzed in addition to related outcomes. Results: We identified 95 patients placed on V‐V ECMO: 61 receiving heparin, 34 bivalirudin. The bivalirudin group had a higher rate of severe COVID‐19, higher BMI, and longer ECMO duration. Despite this, bivalirudin was associated with reduced risk of thrombotic event (HR 0.14, 95% CI 0.06–0.32, p <.001) and increased average lifespan of the circuit membrane lung (16 vs. 10 days, p = 0.004). While there was no difference in major bleeding, the bivalirudin group required fewer transfusions of packed red blood cells and platelets per 100 ECMO days (means of 13 vs. 39, p = 0.004; 5 vs. 19, p =.014, respectively). Lastly, the bivalirudin group had improved survival to ECMO decannulation in univariate analysis (median OS 53 vs. 26 days, p =.015). Conclusions: In this real‐world analysis of bivalirudin versus heparin, bivalirudin is a viable option for V‐V ECMO and associated with lower risk of thrombotic complications and fewer transfusion requirements. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

20. Clinical Correlates of Venetoclax-Based Combination Sensitivities to Augment Acute Myeloid Leukemia Therapy

Author

Eide, Christopher A., primary, Kurtz, Stephen E., additional, Kaempf, Andy, additional, Long, Nicola, additional, Joshi, Sunil Kumar, additional, Nechiporuk, Tamilla, additional, Huang, Ariane, additional, Dibb, Charles A., additional, Taylor, Akosha, additional, Bottomly, Daniel, additional, McWeeney, Shannon K., additional, Minnier, Jessica, additional, Lachowiez, Curtis A., additional, Saultz, Jennifer N., additional, Swords, Ronan T., additional, Agarwal, Anupriya, additional, Chang, Bill H., additional, Druker, Brian J., additional, and Tyner, Jeffrey W., additional

Published
2023
Full Text
View/download PDF

21. MDS-009 Enhanced Survival of Chronic Myelomonocytic Leukemia (CMML)-Dysplastic Over the Proliferative Subtype After Allogeneic Hematopoietic Cell Transplantation: A Tertiary Center Experience

Author

Niehus, Hunter, primary, Sabile, Jean, additional, Maziarz, Richard T., additional, Meyers, Gabrielle, additional, Cook, Rachel, additional, Gandhi, Arpita, additional, Saultz, Jennifer N., additional, Rakshe, Shauna, additional, Kaempf, Andy, additional, Braun, Theodore, additional, and Migdady, Yazan, additional

Published
2023
Full Text
View/download PDF

22. POSTER: MDS-009 Enhanced Survival of Chronic Myelomonocytic Leukemia (CMML)-Dysplastic Over the Proliferative Subtype After Allogeneic Hematopoietic Cell Transplantation: A Tertiary Center Experience

Author

Niehus, Hunter, primary, Sabile, Jean, additional, Maziarz, Richard T., additional, Meyers, Gabrielle, additional, Cook, Rachel, additional, Gandhi, Arpita, additional, Saultz, Jennifer N., additional, Rakshe, Shauna, additional, Kaempf, Andy, additional, Braun, Theodore, additional, and Migdady, Yazan, additional

Published
2023
Full Text
View/download PDF

25. Molecularly targeted drug combinations demonstrate selective effectiveness for myeloid- and lymphoidderived hematologic malignancies

Author

Kurtz, Stephen E., Eide, Christopher A., Kaempf, Andy, Khanna, Vishesh, Savage, Samantha L., Rofelty, Angela, English, Isabel, Ho, Hibery, Pandya, Ravi, Bolosky, William J., Poon, Hoifung, Deininger, Michael W., Collins, Robert, Swords, Ronan T., Watts, Justin, Pollyea, Daniel A., Medeiros, Bruno C., Traer, Elie, Tognon, Cristina E., Mori, Motomi, Druker, Brian J., and Tyner, Jeffrey W.

Published
2017

27. Role of platelet count in a murine stasis model of deep vein thrombosis.

Author

Mathews, Rick, Setthavongsack, Naly, Le-Cook, Anh, Kaempf, Andy, Loftis, Jennifer M., Woltjer, Randall L., Lorentz, Christina U., Revenko, Alexey, Hinds, Monica T., and Nguyen, Khanh P.

Subjects
VENOUS thrombosis, PLATELET count, POSTTHROMBOTIC syndrome, THROMBOTIC thrombocytopenic purpura, MUSCLE cells
Abstract

Platelets are core components of thrombi but their effect on thrombus burden during deep vein thrombosis (DVT) has not been fully characterized. We examined the role of thrombopoietin-altered platelet count on thrombus burden in a murine stasis model of DVT. To modulate platelet count compared to baseline, CD1 mice were pretreated with thrombopoietin antisense oligonucleotide (THPO-ASO, 56% decrease), thrombopoietin mimetic (TPO-mimetic, 36% increase), or saline (within 1%). Thrombi and vein walls were examined on postoperative days (POD) 3 and 7. Thrombus weights on POD 3 were not different between treatment groups (p = .84). The mean thrombus weights on POD 7 were significantly increased in the TPO-mimetic cohort compared to the THPO-ASO (p = .005) and the saline (p = .012) cohorts. Histological grading at POD 3 revealed a significantly increased smooth muscle cell presence in the thrombi and CD31 positive channeling in the vein wall of the TPOmimetic cohort compared to the saline and THPO-ASO cohorts (p < .05). No differences were observed in histology on POD 7. Thrombopoietin-induced increased platelet count increased thrombus weight on POD 7 indicating platelet count may regulate thrombus burden during early resolution of venous thrombi in this murine stasis model of DVT. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

28. Functional genomic landscape of acute myeloid leukaemia

Author

Tyner, Jeffrey W., Tognon, Cristina E., Bottomly, Daniel, Wilmot, Beth, Kurtz, Stephen E., Savage, Samantha L., Long, Nicola, Schultz, Anna Reister, Traer, Elie, Abel, Melissa, Agarwal, Anupriya, Blucher, Aurora, Borate, Uma, Bryant, Jade, Burke, Russell, Carlos, Amy, Carpenter, Richie, Carroll, Joseph, Chang, Bill H., Coblentz, Cody, d’Almeida, Amanda, Cook, Rachel, Danilov, Alexey, Dao, Kim-Hien T., Degnin, Michie, Devine, Deirdre, Dibb, James, Edwards, V, David K., Eide, Christopher A., English, Isabel, Glover, Jason, Henson, Rachel, Ho, Hibery, Jemal, Abdusebur, Johnson, Kara, Johnson, Ryan, Junio, Brian, Kaempf, Andy, Leonard, Jessica, Lin, Chenwei, Liu, Selina Qiuying, Lo, Pierrette, Loriaux, Marc M., Luty, Samuel, Macey, Tara, MacManiman, Jason, Martinez, Jacqueline, Mori, Motomi, Nelson, Dylan, Nichols, Ceilidh, Peters, Jill, Ramsdill, Justin, Rofelty, Angela, Schuff, Robert, Searles, Robert, Segerdell, Erik, Smith, Rebecca L., Spurgeon, Stephen E., Sweeney, Tyler, Thapa, Aashis, Visser, Corinne, Wagner, Jake, Watanabe-Smith, Kevin, Werth, Kristen, Wolf, Joelle, White, Libbey, Yates, Amy, Zhang, Haijiao, Cogle, Christopher R., Collins, Robert H., Connolly, Denise C., Deininger, Michael W., Drusbosky, Leylah, Hourigan, Christopher S., Jordan, Craig T., Kropf, Patricia, Lin, Tara L., Martinez, Micaela E., Medeiros, Bruno C., Pallapati, Rachel R., Pollyea, Daniel A., Swords, Ronan T., Watts, Justin M., Weir, Scott J., Wiest, David L., Winters, Ryan M., McWeeney, Shannon K., and Druker, Brian J.

Published
2018
Full Text
View/download PDF

33. Supplementary Table 2 from The Chronic Lymphocytic Leukemia Comorbidity Index (CLL-CI): A Three-Factor Comorbidity Model

Author

Gordon, Max J., primary, Kaempf, Andy, primary, Sitlinger, Andrea, primary, Shouse, Geoffrey, primary, Mei, Matthew, primary, Brander, Danielle M., primary, Salous, Tareq, primary, Hill, Brian T., primary, Alqahtani, Hamood, primary, Choi, Michael, primary, Churnetski, Michael C., primary, Cohen, Jonathon B., primary, Stephens, Deborah M., primary, Siddiqi, Tanya, primary, Rivera, Xavier, primary, Persky, Daniel, primary, Wisniewski, Paul, primary, Patel, Krish, primary, Shadman, Mazyar, primary, Park, Byung, primary, and Danilov, Alexey V., primary

Published
2023
Full Text
View/download PDF

34. Supplementary Table 5 from The Chronic Lymphocytic Leukemia Comorbidity Index (CLL-CI): A Three-Factor Comorbidity Model

Author

Gordon, Max J., primary, Kaempf, Andy, primary, Sitlinger, Andrea, primary, Shouse, Geoffrey, primary, Mei, Matthew, primary, Brander, Danielle M., primary, Salous, Tareq, primary, Hill, Brian T., primary, Alqahtani, Hamood, primary, Choi, Michael, primary, Churnetski, Michael C., primary, Cohen, Jonathon B., primary, Stephens, Deborah M., primary, Siddiqi, Tanya, primary, Rivera, Xavier, primary, Persky, Daniel, primary, Wisniewski, Paul, primary, Patel, Krish, primary, Shadman, Mazyar, primary, Park, Byung, primary, and Danilov, Alexey V., primary

Published
2023
Full Text
View/download PDF

35. Supplementary Table 3 from The Chronic Lymphocytic Leukemia Comorbidity Index (CLL-CI): A Three-Factor Comorbidity Model

Author

Gordon, Max J., primary, Kaempf, Andy, primary, Sitlinger, Andrea, primary, Shouse, Geoffrey, primary, Mei, Matthew, primary, Brander, Danielle M., primary, Salous, Tareq, primary, Hill, Brian T., primary, Alqahtani, Hamood, primary, Choi, Michael, primary, Churnetski, Michael C., primary, Cohen, Jonathon B., primary, Stephens, Deborah M., primary, Siddiqi, Tanya, primary, Rivera, Xavier, primary, Persky, Daniel, primary, Wisniewski, Paul, primary, Patel, Krish, primary, Shadman, Mazyar, primary, Park, Byung, primary, and Danilov, Alexey V., primary

Published
2023
Full Text
View/download PDF

36. Supplementary Fig 1 from The Chronic Lymphocytic Leukemia Comorbidity Index (CLL-CI): A Three-Factor Comorbidity Model

Author

Gordon, Max J., primary, Kaempf, Andy, primary, Sitlinger, Andrea, primary, Shouse, Geoffrey, primary, Mei, Matthew, primary, Brander, Danielle M., primary, Salous, Tareq, primary, Hill, Brian T., primary, Alqahtani, Hamood, primary, Choi, Michael, primary, Churnetski, Michael C., primary, Cohen, Jonathon B., primary, Stephens, Deborah M., primary, Siddiqi, Tanya, primary, Rivera, Xavier, primary, Persky, Daniel, primary, Wisniewski, Paul, primary, Patel, Krish, primary, Shadman, Mazyar, primary, Park, Byung, primary, and Danilov, Alexey V., primary

Published
2023
Full Text
View/download PDF

37. Supplementary Fig 3 from The Chronic Lymphocytic Leukemia Comorbidity Index (CLL-CI): A Three-Factor Comorbidity Model

Author

Gordon, Max J., primary, Kaempf, Andy, primary, Sitlinger, Andrea, primary, Shouse, Geoffrey, primary, Mei, Matthew, primary, Brander, Danielle M., primary, Salous, Tareq, primary, Hill, Brian T., primary, Alqahtani, Hamood, primary, Choi, Michael, primary, Churnetski, Michael C., primary, Cohen, Jonathon B., primary, Stephens, Deborah M., primary, Siddiqi, Tanya, primary, Rivera, Xavier, primary, Persky, Daniel, primary, Wisniewski, Paul, primary, Patel, Krish, primary, Shadman, Mazyar, primary, Park, Byung, primary, and Danilov, Alexey V., primary

Published
2023
Full Text
View/download PDF

40. Overall Survival in Myelofibrosis Treated with Allogeneic Hematopoietic Cell Transplant Is Impacted By Reversal of Marrow Fibrosis: A Single Institution Experience from Oregon Health and Science University

Author

Gandhi, Arpita, primary, Guitierrez, Anthony, additional, Kaempf, Andy, additional, Saultz, Dr. Jennifer N, additional, Xie, Wei, additional, Cook, Rachel, additional, Migdady, Yazan, additional, Schachter, Levanto, additional, Slater, Susan, additional, Meyers, Gabrielle, additional, and Maziarz, Richard T, additional

Published
2023
Full Text
View/download PDF

41. Pre-Transplant Measurable Residual Disease By Next-Generation Sequencing Is a Better Predictor of Relapse Compared to BCR-ABL PCR in Adult Patients with Ph+ Acute Lymphoblastic Leukemia

Author

Dekker, Simone E., primary, Sabile, Jean M.G., additional, Liang, Emily C., additional, DaSilva, Brandon A, additional, Torelli, Stefan, additional, Kaempf, Andy, additional, Lim, Jeong Youn, additional, Shiraz, Parveen, additional, Hayes-Lattin, Brandon, additional, Muffly, Lori, additional, and Leonard, Jessica T., additional

Published
2023
Full Text
View/download PDF

42. A retrospective validation of the IPSS-M molecular score in primary and therapy-related myelodysplastic syndromes (MDS).

Author

Sabile, Jean M. G., Kaempf, Andy, Tomic, Kaitlyn, Manu, Gurusidda P., Swords, Ronan, and Migdady, Yazan

Subjects
*MYELODYSPLASTIC syndromes, *ACUTE myeloid leukemia, *OVERALL survival, *CANCER remission
Abstract

A molecular scoring system (IPSS-M) was recently proposed for myelodysplastic syndrome (MDS). We conducted a retrospective study of adults with MDS referred 2019–2021. The primary outcomes were leukemia-free survival (LFS) and overall survival (OS). One hundred and forty-four patients diagnosed between 2011 and 2021 were analyzed. After IPSS-M re-stratification, 33% of patients were up-staged and 11% down-staged. Median follow-up was 2.8 years and 53 patients died (37%). Cumulative incidence of acute myeloid leukemia (AML) transformation was 20% at 3 years post-diagnosis. International Prognostic Scoring System (IPSS), revised version (IPSS-R) was significantly associated with LFS (log-rank p = 9.2e–05; 'very high' vs. 'low' risk HR = 3.85, p = 5.8e–04) and OS (log-rank p = 7.2e–06; 'very high' vs. 'low' HR = 5.09, p = 1.7e–04). IPSS-M was also a significant predictor of LFS (log-rank p = 1.1e–06; 'very high' vs. 'low' HR = 4.97, p = 2.2e–05) and OS (log-rank p = 4.8e–07; 'very high' vs. 'low' HR = 6.42, p = 2.5e–05) while providing better discrimination than IPSS-R for both outcomes. This mutation-incorporating prognostic index has greater discriminative potential than IPSS-R to predict AML transformation and any-cause mortality. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

43. The Aryl Hydrocarbon Receptor Defines a Unique Genomic and Immune Signature in AML Characterized By Monocytic Differentiation, Venetoclax Resistance and Is Targetable By Ahr Antagonist

Author

Saultz, Jennifer N., primary, Bottomly, Daniel, additional, Burns, Faith, additional, Byrd, Kaelan, additional, Kosaka, Yoko, additional, McWeeney, Shannon K., additional, Kurtz, Stephen E., additional, Fan, Guang, additional, Kaempf, Andy, additional, McGovern, Karen, additional, Wang, Lei, additional, Sanchez-Martin, Marta, additional, Kaufman, Dan S, additional, Lind, Evan F., additional, and Tyner, Jeffrey W., additional

Published
2022
Full Text
View/download PDF

45. Impact of a Validated Composite Comorbidity Score on Outcomes in Patients Treated with CAR T-Cell Therapy for Diffuse Large B Cell Lymphoma (DLBCL): A Multicenter Real-World Evidence (RWE) Study

Author

Shouse, Geoffrey, primary, Kaempf, Andy, additional, Gordon, Max J., additional, Yashar, David, additional, Sigmund, Audrey M., additional, Smilnak, Gordon, additional, Bair, Steven M., additional, Mian, Agrima, additional, Fitzgerald, Lindsey A., additional, Bajwa, Amneet, additional, Jaglowski, Samantha, additional, Bailey, Neil, additional, Shadman, Mazyar, additional, Patel, Krish, additional, Stephens, Deborah M., additional, Kamdar, Manali, additional, Hill, Brian T., additional, Gauthier, Jordan, additional, Karmali, Reem, additional, Nastoupil, Loretta J., additional, Kittai, Adam S, additional, and Danilov, Alexey V, additional

Published
2022
Full Text
View/download PDF

46. Defining Clinical and Molecular Biomarkers for Venetoclax-Based Drug Combinations to Augment AML Therapy

Author

Eide, Christopher A., primary, Kurtz, Stephen E., additional, Kaempf, Andy, additional, Long, Nicola, additional, Joshi, Sunil K, additional, Nechiporuk, Tamilla, additional, Huang, Ariane, additional, Dibb, Charles, additional, Bottomly, Daniel, additional, McWeeney, Shannon K., additional, Chang, Bill H., additional, Druker, Brian J., additional, and Tyner, Jeffrey W., additional

Published
2022
Full Text
View/download PDF

48. Abstract A27: Impact of a validated composite comorbidity score on outcomes in patients treated with CAR T-cell therapy for diffuse large B cell lymphoma (DLBCL): A multicenter real-world evidence (RWE) study

Author

Shouse, Geoffrey, primary, Kaempf, Andy, additional, Gordon, Max, additional, Yashar, David, additional, Sigmund, Audrey M, additional, Smilnak, Gordon, additional, Bair, Steven M, additional, Mian, Agrima, additional, Fitzgerald, Lindsey, additional, Bajwa, Amneet, additional, Jaglowski, Samantha, additional, Bailey, Neil, additional, Shadman, Mayzar, additional, Patel, Krish, additional, Stephens, Deborah M, additional, Kamdar, Manali, additional, Hill, Brian T, additional, Gauthier, Jordon, additional, Karmali, Reem, additional, Nastoupil, Loretta, additional, Kittai, Adam S, additional, and Danilov, Alexey V, additional

Published
2022
Full Text
View/download PDF

49. Integrative analysis of drug response and clinical outcome in acute myeloid leukemia

Author

Bottomly, Daniel, primary, Long, Nicola, additional, Schultz, Anna Reister, additional, Kurtz, Stephen E., additional, Tognon, Cristina E., additional, Johnson, Kara, additional, Abel, Melissa, additional, Agarwal, Anupriya, additional, Avaylon, Sammantha, additional, Benton, Erik, additional, Blucher, Aurora, additional, Borate, Uma, additional, Braun, Theodore P., additional, Brown, Jordana, additional, Bryant, Jade, additional, Burke, Russell, additional, Carlos, Amy, additional, Chang, Bill H., additional, Cho, Hyun Jun, additional, Christy, Stephen, additional, Coblentz, Cody, additional, Cohen, Aaron M., additional, d’Almeida, Amanda, additional, Cook, Rachel, additional, Danilov, Alexey, additional, Dao, Kim-Hien T., additional, Degnin, Michie, additional, Dibb, James, additional, Eide, Christopher A., additional, English, Isabel, additional, Hagler, Stuart, additional, Harrelson, Heath, additional, Henson, Rachel, additional, Ho, Hibery, additional, Joshi, Sunil K., additional, Junio, Brian, additional, Kaempf, Andy, additional, Kosaka, Yoko, additional, Laderas, Ted, additional, Lawhead, Matt, additional, Lee, Hyunjung, additional, Leonard, Jessica T., additional, Lin, Chenwei, additional, Lind, Evan F., additional, Liu, Selina Qiuying, additional, Lo, Pierrette, additional, Loriaux, Marc M., additional, Luty, Samuel, additional, Maxson, Julia E., additional, Macey, Tara, additional, Martinez, Jacqueline, additional, Minnier, Jessica, additional, Monteblanco, Andrea, additional, Mori, Motomi, additional, Morrow, Quinlan, additional, Nelson, Dylan, additional, Ramsdill, Justin, additional, Rofelty, Angela, additional, Rogers, Alexandra, additional, Romine, Kyle A., additional, Ryabinin, Peter, additional, Saultz, Jennifer N., additional, Sampson, David A., additional, Savage, Samantha L., additional, Schuff, Robert, additional, Searles, Robert, additional, Smith, Rebecca L., additional, Spurgeon, Stephen E., additional, Sweeney, Tyler, additional, Swords, Ronan T., additional, Thapa, Aashis, additional, Thiel-Klare, Karina, additional, Traer, Elie, additional, Wagner, Jake, additional, Wilmot, Beth, additional, Wolf, Joelle, additional, Wu, Guanming, additional, Yates, Amy, additional, Zhang, Haijiao, additional, Cogle, Christopher R., additional, Collins, Robert H., additional, Deininger, Michael W., additional, Hourigan, Christopher S., additional, Jordan, Craig T., additional, Lin, Tara L., additional, Martinez, Micaela E., additional, Pallapati, Rachel R., additional, Pollyea, Daniel A., additional, Pomicter, Anthony D., additional, Watts, Justin M., additional, Weir, Scott J., additional, Druker, Brian J., additional, McWeeney, Shannon K., additional, and Tyner, Jeffrey W., additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results